The drugmaker, along with partner BioNTech, plans to submit the new data to the FDA this week. The agency has scheduled a meeting for outside experts to review the data in mid-June.
Original source: https://www.healthcaredive.com/news/pfizer-biontech-covid-vaccine-young-children-fda-review/624209/